Get notified of page updates

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Prevention

Clinicaltrials.gov identifier:
NCT04067726

Study Contact Information:


 

 

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.

NOTE: This study is no longer enrolling people

This Study is Open To:

NOTE: This study is no longer enrolling people

This Study is NOT Open To:

NOTE: This study is no longer enrolling people

Study Contact Information:


 

 

Prevention

Clinicaltrials.gov identifier:
NCT04067726

Study Contact Information:


 

 

PRINTER FRIENDLY PAGE